Stoke Therapeutics (NASDAQ:STOK) Insider Barry Ticho Sells 3,662 Shares

Stoke Therapeutics, Inc. (NASDAQ:STOK) insider Barry Ticho sold 3,662 shares of the stock in a transaction dated Friday, December 5th. The shares were sold at an average price of $31.34, for a total transaction of $114,767.08. Following the transaction, the insider directly owned 19,798 shares of the company’s stock, valued at $620,469.32. This trade represents a 15.61% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Barry Ticho also recently made the following trade(s):

• On Thursday, December 4th, Barry Ticho sold 1,696 shares of Stoke Therapeutics stock. The stock was sold at an average price of $30.87, for a total value of $52,355.52.
• On Wednesday, December 3rd, Barry Ticho sold 2,014 shares of Stoke Therapeutics stock. The shares were sold at an average price of $30.65, for a total value of $61,729.10.
• On Tuesday, December 2nd, Barry Ticho sold 2,006 shares of Stoke Therapeutics stock. The shares were sold at an average price of $29.78, for a total transaction of $59,738.68.
• On Monday, November 3rd, Barry Ticho sold 5,931 shares of Stoke Therapeutics stock. The shares were sold at an average price of $25.72, for a total transaction of $152,545.32.

Stoke Therapeutics Stock Performance

STOK stock traded down $0.18 during trading on Friday, hitting $30.87. 602,753 shares of the company’s stock traded hands, compared to its average volume of 917,923. Stoke Therapeutics, Inc. has a 52 week low of $5.35 and a 52 week high of $38.69. The stock has a market capitalization of $1.76 billion, a price-to-earnings ratio of 46.07 and a beta of 1.14. The business has a fifty day simple moving average of $28.90 and a 200 day simple moving average of $19.69.

Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.54) by ($0.11). The company had revenue of $10.63 million for the quarter, compared to the consensus estimate of $6.06 million. Stoke Therapeutics had a return on equity of 13.28% and a net margin of 19.73%. Research analysts forecast that Stoke Therapeutics, Inc. will post -2.01 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Stoke Therapeutics

A number of institutional investors have recently modified their holdings of the stock. Wellington Management Group LLP raised its stake in shares of Stoke Therapeutics by 0.9% during the first quarter. Wellington Management Group LLP now owns 135,960 shares of the company’s stock valued at $904,000 after acquiring an additional 1,148 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Stoke Therapeutics by 5.0% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,167 shares of the company’s stock worth $162,000 after purchasing an additional 1,149 shares in the last quarter. CANADA LIFE ASSURANCE Co increased its holdings in Stoke Therapeutics by 12.3% during the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 11,978 shares of the company’s stock worth $296,000 after purchasing an additional 1,313 shares during the period. BNP Paribas Financial Markets raised its position in Stoke Therapeutics by 66.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock valued at $48,000 after purchasing an additional 1,668 shares in the last quarter. Finally, Generali Investments Management Co LLC purchased a new stake in shares of Stoke Therapeutics in the 3rd quarter worth $41,000.

Wall Street Analyst Weigh In

STOK has been the topic of a number of analyst reports. Chardan Capital upgraded shares of Stoke Therapeutics to a “strong-buy” rating in a research report on Wednesday, November 19th. Wedbush lifted their price target on shares of Stoke Therapeutics from $22.00 to $32.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 5th. BTIG Research reissued a “buy” rating and issued a $39.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday, November 5th. Weiss Ratings restated a “hold (c)” rating on shares of Stoke Therapeutics in a research report on Monday. Finally, Canaccord Genuity Group upped their target price on Stoke Therapeutics from $24.00 to $28.00 and gave the company a “buy” rating in a research note on Wednesday, November 5th. Two equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $31.00.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.